Amicus Therapeutics, Inc.

Total Valuation

Amicus Therapeutics, Inc. carries a market capitalization of 4.55B, placing it among publicly traded companies globally. Its enterprise value stands at 4.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Amicus Therapeutics, Inc. currently has 310.85M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 6.92, and the price-to-book ratio stands at -1.59.

Enterprise Valuation

On an enterprise value basis, Amicus Therapeutics, Inc. trades at an EV/EBITDA multiple of 108.14 and an EV/FCF ratio of 702.09. The EV/Sales ratio of 7.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 131.53 provides insight into valuation relative to core operating earnings.

Financial Position

Amicus Therapeutics, Inc. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 161.30, indicating elevated leverage, while an interest coverage ratio of 0.91 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Amicus Therapeutics, Inc. has paid 27.30M in income taxes, reflecting an effective tax rate of 14,293.72.

Stock Price Statistics

Amicus Therapeutics, Inc.'s stock has gained approximately 132.21154% over the past 52 weeks. The 50-day moving average sits at 14.40, while the 200-day moving average is 10.88.

Income Statement

Over the trailing twelve months, Amicus Therapeutics, Inc. generated 634.21M in revenue and converted that into -27.11M in net income, yielding earnings per share of -0.09. EBITDA reached 41.95M, while operating income came in at 34.49M.

Balance Sheet

Amicus Therapeutics, Inc. holds 293.54M in cash and equivalents against 442.36M in total debt, resulting in a net debt position of 178.65M. Total book value stands at -2.76B, with working capital of 438.35M providing operational flexibility.

Cash Flow

Amicus Therapeutics, Inc. produced 33.15M in operating cash flow over the past twelve months.

Margins

Amicus Therapeutics, Inc. operates with a gross margin of 88.50, reflecting its pricing power and cost economics. The operating margin of 5.44 and net profit margin of -4.27 provide insight into operational efficiency.

Dividends & Yields

Scores

Amicus Therapeutics, Inc. posts an Altman Z-Score of 0.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.